Evidence map›Paper›PMID 25987466›Full record

ArticleMolecular imaging and biology2016

In Vivo Detection of miRNA Expression in Tumors Using an Activatable Nanosensor.

Byunghee Yoo, Amol Kavishwar, Alana Ross, Pamela Pantazopoulos, Anna Moore, Zdravka Medarova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Byunghee YooMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA.
Amol KavishwarMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA.
Alana RossMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA.
Pamela PantazopoulosMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA.
Anna MooreMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA. amoore@helix.mgh.harvard.edu.
Zdravka MedarovaMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA. zmedarova@mgh.harvard.edu.

Funding

NUCLEAR MAGNETIC RESONANCE RESEARCHT32CA009502 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MOORE, ANNA · 1985 to 2013
$2.0M
MicroRNA Therapy for Lymph Node Metastatic Breast CancerR01CA163461 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MEDAROVA, ZDRAVKA O · 2012 to 2016
$1.9M
IVIS Spectrum Imaging SystemS10RR025504 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI MOORE, ANNA · 2009 to 2009
$341k
NCI NIH HHS 5T32CA009502NCI NIH HHS R01 CA163461NCI NIH HHS R01CA16346101A1NCI NIH HHS T32 CA009502NCRR NIH HHS S10 RR025504
6 · The paper itself

Abstract

purposeThe development of tools for the analysis of microRNA (miRNA) function in tumors can advance our diagnostic and prognostic capabilities. Here, we describe the development of technology for the profiling of miRNA expression in the tumors of live animals. PROCEDURES: The approach is based on miRNA nanosensors consisting of sensor oligonucleotides conjugated to magnetic nanoparticles for systemic delivery. Feasibility was demonstrated for the detection of miR-10b, implicated in epithelial to mesenchymal transition and the development of metastasis. The miR-10b nanosensor was tested in vivo in two mouse models of cancer. In the first model, mice were implanted subcutaneously with MDA-MB-231-luc-D3H2LN tumors, in which miR-10b was inhibited. In the second model, mice were implanted bilaterally with metastatic MDA-MB-231 and nonmetastatic MCF-7 cells. The nanosensors were injected intravenously, and fluorescence intensity in the tumors was monitored over time.

resultsWe showed that the described nanosensors are capable of discriminating between tumors based on their expression of miR-10b. Radiant efficiency was higher in the miR-10b-active tumors than in the miR-10b-inhibited tumors and in the MDA-MB-231 tumors relative to the MCF-7 tumors.

conclusionsThe described technology provides an important tool that could be used to answer questions about microRNA function in cancer.

Indexed as

AnimalsBiosensing TechniquesCell Line, TumorDisease Models, AnimalFemaleFluorescenceGene Expression Regulation, NeoplasticHumansMice, NudeMicroRNAsNanoparticlesNeoplasmsOligonucleotidesXenograft Model Antitumor AssaysMicroRNAsOligonucleotidesActivatable probesCancerFluorescenceMagnetic nanoparticlesMetastasismiRNANanosensorsOligonucleotides

Identifiers

PMID25987466
PMCPMC4774252

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.